ERRγ ligand HPB2 upregulates BDNF-TrkB and enhances dopaminergic neuronal phenotype. (March 2021)

• Record Type: Journal Article
• Authors: Kim, Hyo In; Lee, Seungbeom; Lim, Juhee; Chung, Sungkyun; Koo, Tae-Sung; Ji, Yu-Geun; Suh, Young-Ger; Son, Woo Sung; Kim, Seok-Ho; Choi, Hyun Jin
• Is Part Of: Pharmacological research. Volume 165(2021)
• Publication Date: 2021-03
• Subjects: BDNF brain derived neurotrophic factor -- CREB cAMP-response element binding protein -- DAergic dopaminergic -- DAT dopamine transporter -- ERK extracellular-signal-regulated kinase -- ERRγ estrogen‐related receptor gamma -- HPB2 (E)-4-hydroxy-N'-(4-(phenylethynyl)benzylidene)benzohydrazide -- PD Parkinson's disease -- TH tyrosine hydroxylase -- TrkB tropomyosin receptor kinase B -- VM ventral mesencephalic; GSK4716 (PubChem CID: 5331325) -- GSK5182 (PubChem CID: 6852176) -- PD98059 (PubChem CID: 4713) -- ANA-12 (PubChem CID: 29799722) -- SB203580 (PubChem CID: 176155) -- SP600125 (PubChem CID: 8515); BDNF -- Dopaminergic neuron -- ERRγ -- HPB2 -- Parkinson's disease; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2021.105423
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Brain derived neurotrophic factor (BDNF) promotes maturation of dopaminergic (DAergic) neurons in the midbrain and positively regulates their maintenance and outgrowth. Therefore, understanding the mechanisms regulating the BDNF signaling pathway in DAergic neurons may help discover potential therapeutic strategies for neuropsychological disorders associated with dysregulation of DAergic neurotransmission. Because estrogen‐related receptor gamma (ERRγ) is highly expressed in both the fetal nervous system and adult brains during DAergic neuronal differentiation, and it is involved in regulating the DAergic neuronal phenotype, we asked in this study whether ERRγ ligand regulates BDNF signaling and subsequent DAergic neuronal phenotype. Based on the X-ray crystal structures of the ligand binding domain of ERRγ, we designed and synthesized the ERRγ agonist, ( E )-4-hydroxy- N '-(4-(phenylethynyl)benzylidene)benzohydrazide (HPB2) ( K d value, 8.35 μmol/L). HPB2 increased BDNF mRNA and protein levels, and enhanced the expression of the BDNF receptor tropomyosin receptor kinase B (TrkB) in human neuroblastoma SH-SY5Y, differentiated Lund human mesencephalic (LUHMES) cells, and primary ventral mesencephalic (VM) neurons. HPB2-induced upregulation of BDNF was attenuated by GSK5182, an antagonist of ERRγ, and siRNA-mediated ERRγ silencing. HPB2-induced activation of extracellular-signal-regulated kinase (ERK) and phosphorylation of cAMP-response element binding protein (CREB) was responsible for BDNF upregulation in SH-SY5Y cells. HPB2 enhanced the DAergic neuronal phenotype, namely upregulation of tyrosine hydroxylase (TH) and DA transporter (DAT) with neurite outgrowth, both in SH-SY5Y and primary VM neurons, which was interfered by the inhibition of BDNF-TrkB signaling, ERRγ knockdown, or blockade of ERK activation. HPB2 also upregulated BDNF and TH in the striatum and induced neurite elongation in the substantia nigra of mice brain. In conclusion, ERRγ activation regulated BDNF expression and the subsequent DAergic neuronal phenotype in neuronal cells. Our results might provide new insights into the mechanism underlying the regulation of BDNF expression, leading to novel therapeutic strategies for neuropsychological disorders associated with DAergic dysregulation.